RxDoctor Payments Data

Daniel Martin, MD

Family Medicine · Springfield, PANPI 1598767816

Payments from drug & device makers

$6,765in general payments, 2019–2025

Across 439 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$888
  • AbbVie$665
  • Boehringer Ingelheim$624
  • AstraZeneca$435
  • Merck$390
  • Lilly USA, LLC$356
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,66799%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,765 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$126,839
Medicare patients
454
Services billed
3,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$172,578
EliquisApixaban269$163,132
TrulicityDulaglutide76$94,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$71,830
XareltoRivaroxaban89$62,667
MounjaroTirzepatide48$51,637
JanuviaSitagliptin Phosphate34$51,118
OzempicSemaglutide37$43,746
InvokanaCanagliflozin16$26,217
EntrestoSacubitril/Valsartan44$23,900
FarxigaDapagliflozin Propanediol22$22,817
MyrbetriqMirabegron46$20,829
Spiriva HandihalerTiotropium Bromide17$14,446
JanumetSitagliptin Phos/Metformin Hcl16$13,397
Atorvastatin Calcium700$12,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$624$179,658163 claims
PfizerEliquis, Abrysvo$309$169,069286 claims
Lilly USA, LLCTrulicity, Mounjaro$356$145,782124 claims
Johnson & JohnsonXarelto, Invokana$254$88,884105 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$303$86,853133 claims
MerckJanuvia, Janumet$390$64,51550 claims
Novo NordiskOzempic$888$43,74637 claims
AstraZenecaFarxiga, Brilinta$435$27,67941 claims
NovartisEntresto$70$23,90044 claims
Astellas Pharma US IncMyrbetriq$286$20,82946 claims
AbbVieRestasis$665$4,72713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Springfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →